Lara M Simpson
Overview
Explore the profile of Lara M Simpson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamal J, Martinez J, Osani M, Du X, Simpson L, Davis B
JAMA Netw Open
. 2023 Dec;
6(12):e2344998.
PMID: 38048133
Importance: The long-term relative risk of antihypertensive treatments with regard to mortality and morbidity is not well understood. Objective: To determine the long-term posttrial risk of primary and secondary outcomes...
2.
Du X, Martinez J, Yamal J, Simpson L, Davis B
Front Cardiovasc Med
. 2023 Dec;
10:1272385.
PMID: 38045916
Purpose: This study aimed to determine the 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drug use. Methods: This is a post-trial passive follow-up...
3.
Du X, Simpson L, Osani M, Yama J, Davis B
J Alzheimers Dis Parkinsonism
. 2022 May;
12(3).
PMID: 35571234
Background: There is no any large randomized clinical trial of antihypertensive drug treatment with 18-year passive follow-up to examine the risk of Alzheimer's Disease (AD) or Related Dementias (ADRD). Methods:...
4.
Du X, Simpson L, Tandy B, Bettencourt J, Davis B
Int J Hypertens
. 2021 Dec;
2021:2261144.
PMID: 34925915
Background: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ended in 2002, but it is important to study its long-term outcomes during the posttrial period by incorporating posttrial...
5.
Du X, Simpson L, Tandy B, Bettencourt J, Davis B
PLoS One
. 2021 Nov;
16(11):e0260107.
PMID: 34793552
Objectives: This post-trial data linkage analysis was to utilize the data of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants linked with their Medicare data to examine...
6.
Bowling C, Sloane R, Pieper C, Luciano A, Davis B, Simpson L, et al.
J Hypertens
. 2021 Jul;
39(11):2258-2264.
PMID: 34232161
Objectives: Sustaining SBP control reduces the risk for cardiovascular events that impair function but its association with nursing home admission has not been well studied. Methods: We conducted an analysis...
7.
Bowling C, Sloane R, Pieper C, Luciano A, Davis B, Simpson L, et al.
J Gen Intern Med
. 2021 Feb;
36(8):2221-2229.
PMID: 33564944
Background: Clustering of chronic conditions is associated with high healthcare costs. Sustaining blood pressure (BP) control could be a strategy to prevent high-cost multimorbidity clusters. Objective: To determine the association...
8.
Bolli R, Perin E, Willerson J, Yang P, Traverse J, Henry T, et al.
JACC CardioOncol
. 2021 Jan;
2(4):581-595.
PMID: 33403362
Background: Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach...
9.
Bowling C, Sloane R, Pieper C, Luciano A, Davis B, Simpson L, et al.
J Am Geriatr Soc
. 2020 Jun;
68(9):2059-2066.
PMID: 32501546
Background/objectives: Due to the high costs and excess mortality associated with multimorbidity, there is a need to develop approaches for delaying its progression. High blood pressure (BP) is a common...
10.
Ho C, Sanders S, Breslin M, Doust J, Reid C, Davis B, et al.
J Hum Hypertens
. 2020 Mar;
34(4):261-270.
PMID: 32152453
To investigate if there is evidence for a 'legacy effect' for blood pressure (BP) lowering treatment, that is, worse health outcomes from not initiating drug treatment at a systolic BP...